FDA Warning Letter and FDA Form 483 Analysis and Response
No medical device or IVD manufacturer ever wants to receive a Warning Letter and/or Form 483 from the US Food and Drug Administration (FDA). But if you are reading this, it probably means that you have received one as a result of an on-site inspection of your facility.
Officially, the FDA Form 483 is referred to as “Notice of Inspectional Observations.” The 483 is issued by the FDA field investigator after an on-site audit and lists deficiencies of your quality system determined by their inspection. The observations contained in every Form 483 are based on the auditor’s interpretation of the regulations as they relate to your operational quality system. The observations are then submitted to the inspector’s superiors for review.
When you are inspected and the closing meeting with the management occurs, you will be provided the Form 483 prior to the inspector's departure. There are many approaches to consider at this time and Emergo Group can provide support and offer suggestions on the various ways to proceed through and inspection and the requirements afterwards. Depending upon the severity of the findings, you may receive an FDA Warning Letter summarizing the finding of the inspection. DO NOT ignore the required corrections to your quality system identified in your Form 483. You must respond to this and your response is not simply an exercise in writing a tearful letter begging for forgiveness. You should promptly respond to the FDA giving a detailed answer for each item addressed in their letter, and provide a timeline for correcting the issue. The quality and promptness of your response to this letter is extremely important.
How Emergo Group can help you respond to a FDA Warning Letter and Form 483
Emergo Group can assist you prepare an effective response to an FDA 483 and provide you with direction to put your quality system back in full compliance with the regulations. As part of our services, we will:
- Analyze the findings of the FDA 483 and/or Warning Letter
- Propose “Corrective Actions” to be made to your quality system
- Suggest an appropriate timeline which we would expect would to satisfy the FDA
- Chart a course of action for your company
- Assist in correcting FDA findings in the Form 483
- Be available to answer all questions from you or the FDA during your efforts to correct the noted deficiencies
Emergo Group has worked with numerous medical device and IVD companies to formulate proper responses to FDA 483 and Warning Letters and help you get your quality system back into FDA compliance. Contact us today for a free consultation on your situation.
